LG Chem

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, LG Chem sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 1 currently recruiting 12 completed early-phase tilt top decile by trial count

LG Chem: 13 sponsored US clinical trials, 1 recruiting.

LG Chem sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout, with 2 trials.

Top-decile sponsor footprint

LG Chem ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

NCT06332755
COMPLETED Phase 1

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

NCT06189404
COMPLETED Phase 3

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

NCT05586971
COMPLETED Phase 3

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958
COMPLETED Phase 1

A Study of LC542019 in Healthy Subjects and Subjects With T2DM

NCT06333977
COMPLETED Early Phase 1

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT04966325
COMPLETED Phase 1

Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

NCT04886050
COMPLETED Phase 1

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

NCT06040372
COMPLETED Phase 1

Mass Balance Study of [14C]LC350189 in Healthy Volunteers

NCT04070846
COMPLETED Phase 1

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

NCT04139824
COMPLETED Phase 2

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099
COMPLETED Phase 1

Renal PK Study of LC350189

NCT04066712
COMPLETED Phase 1

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

NCT03927677

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 1
Phase 3 2

Therapeutic Areas

Gout 2
Hyperuricemia 2
Renal Cell Carcinoma (RCC) 1
Head and Neck Squamous Cell Carcinoma (HNSCC) 1
Malignant Melanoma 1
Diabetes Mellitus, Type 2 1
Urothelial Carcinoma 1
Healthy 1
Non-small Cell Lung Cancer (NSCLC) 1

What is open in the LG Chem pipeline

1 recruiting of 13 indexed (8% open); 12 completed (92%).

Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Gout (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

LG Chem: open-pipeline peers nationwide

Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

LG Chem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%2%4%6%8%10% Total trials Recruiting share LG ChemAdaptimmuneAgennixAkili Interactive LabsAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical CenterFresenius Medical Care North America
LG Chem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

LG Chem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this LG Chem page

13 registered trials is a research-attention snapshot, not an endorsement of LG Chem or any single study.

  • 1 of LG Chem's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Gout is the condition LG Chem studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

LG Chem pipeline card: 13 registered trials from official public datasets.Report a data error.